Business Description
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Business History
Price Overview
Last updated: May 11, 2026 1:57pm (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.66
Total Equity: $61.05M
Shares: 41,727,983
Total Debt: $35.59M
Cash: $40.55M
EBITDA: -$64.07M
Total Debt: $35.59M
Cash: $40.55M
Revenue: $35.26M
Revenue: $35.26M
Revenue: $35.26M
Total Equity: $61.05M
Tax Rate: 0.0%
Equity: $61.05M
Total Debt: $35.59M
Cash: $40.55M
Current Liabilities: $24.35M
Long-Term Debt: $35.59M
Total Debt: $35.59M
Total Equity: $61.05M
Shares: 41,727,983
Shares: 41,727,983
CapEx: -$1.12M
Shares: 41,727,983
Stock Price: $5.03
Net Income: -$69.11M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $13.7M | $16.4M | $22.4M | $22.5M | $35.3M |
| Cost of Revenue | $14.5M | $13.7M | $19.3M | $21.9M | $19.5M |
| Gross Profit | $-811,000 | $2.7M | $3.1M | $533,000 | $15.8M |
| Operating Expenses | $56.4M | $71.4M | $78.7M | $75.4M | $84.1M |
| Operating Income | -$57.2M | -$68.6M | -$75.6M | -$74.8M | -$68.3M |
| Net Income | -$302.5M | $142.1M | -$60.4M | -$78.6M | -$69.1M |
| EBITDA | -$284.5M | $161.8M | -$48.0M | -$68.7M | -$64.1M |
| EPS | $-14.40 | $6.07 | $-2.20 | $-2.50 | $-1.66 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $33.5M | $35.8M | $75.7M | $74.6M | $40.5M |
| Total Current Assets | $144.4M | $161.2M | $130.0M | $91.4M | $117.5M |
| Total Assets | $198.9M | $177.7M | $138.2M | $100.4M | $126.3M |
| Current Liabilities | $18.4M | $31.5M | $17.3M | $38.8M | $24.3M |
| Long-Term Debt | $59.8M | $56.4M | $41.2M | $34.7M | $35.6M |
| Total Liabilities | $384.5M | $180.2M | $102.4M | $117.0M | $65.2M |
| Total Equity | -$185.5M | -$2.6M | $35.8M | -$16.6M | $61.0M |
| Retained Earnings | -$951.0M | -$808.9M | -$869.3M | -$947.9M | -$1.0B |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$56.1M | -$66.3M | -$70.2M | -$60.5M | -$59.1M |
| Capital Expenditure | $-210,000 | $-312,000 | $-350,000 | -$2.2M | -$1.1M |
| Free Cash Flow | -$56.3M | -$66.6M | -$70.5M | -$62.7M | -$60.2M |
| Acquisitions (net) | $210,000 | -$27.2M | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $15.3M | $2.3M | $39.9M | $-797,000 | -$34.4M |
Analyst Estimates (Annual)
| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$98.3M $89.4M – $109.6M
|
$137.5M $136.1M – $138.8M
|
$201.4M $184.6M – $229.5M
|
$273.9M $251.0M – $312.1M
|
| EBITDA |
-$59.0M -$65.7M – -$53.6M
|
-$82.5M -$83.3M – -$81.7M
|
-$120.8M -$137.7M – -$110.8M
|
-$164.3M -$187.3M – -$150.6M
|
| Net Income |
-$121.7M -$122.4M – -$84.7M
|
-$98.8M -$110.6M – -$46.0M
|
-$52.7M -$62.3M – -$47.0M
|
-$17.0M -$20.1M – -$15.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +19.8% | +36.6% | +0.4% | +56.9% |
| Gross Profit Growth | +436.1% | +13.4% | -82.8% | +2,857.4% |
| Operating Income Growth | -20.0% | -10.2% | +1.0% | +8.7% |
| Net Income Growth | +147.0% | -142.5% | -30.2% | +12.1% |
| EBITDA Growth | +156.9% | -129.7% | -43.1% | +6.7% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-01 | ROEDER DOUGLAS A | A-Award | 2,218.00 | $6.65 | $14,750 |
| 2026-04-01 | Prince Douglas S | A-Award | 1,221.00 | $6.65 | $8,120 |
| 2026-04-01 | Fiorentino Edward | A-Award | 2,124.00 | $6.65 | $14,125 |
| 2026-04-01 | Steven Edelman | A-Award | 1,936.00 | $6.65 | $12,874 |
| 2026-03-13 | ROEDER DOUGLAS A | P-Purchase | 17,500.00 | $5.73 | $100,275 |
| 2026-03-13 | Goodnow Timothy T | P-Purchase | 17,225.00 | $5.79 | $99,733 |
| 2026-01-02 | Prince Douglas S | A-Award | 1,379.00 | $5.89 | $8,122 |
| 2026-01-02 | ROEDER DOUGLAS A | A-Award | 2,504.00 | $5.89 | $14,749 |
| 2026-01-02 | Fiorentino Edward | A-Award | 2,398.00 | $5.89 | $14,124 |
| 2026-01-02 | Steven Edelman | A-Award | 2,185.00 | $5.89 | $12,870 |
| 2025-11-15 | Sullivan Frederick T. | F-InKind | 6,402.00 | $6.26 | $40,077 |
| 2025-11-15 | Kaufman Francine | F-InKind | 4,605.00 | $6.26 | $28,827 |
| 2025-11-15 | JAIN Mukul | F-InKind | 10,317.00 | $6.26 | $64,584 |
| 2025-11-15 | Horton Kenneth L | F-InKind | 5,997.00 | $6.26 | $37,541 |
| 2025-11-15 | Goodnow Timothy T | F-InKind | 27,067.00 | $6.26 | $169,439 |
| 2025-11-10 | Steven Edelman | P-Purchase | 10,000.00 | $6.55 | $65,500 |
| 2025-11-07 | ROEDER DOUGLAS A | P-Purchase | 15,000.00 | $5.83 | $87,450 |
| 2025-11-07 | Sullivan Frederick T. | P-Purchase | 5,415.00 | $5.88 | $31,840 |
| 2025-11-07 | Goodnow Timothy T | P-Purchase | 17,210.00 | $5.87 | $101,023 |
| 2025-10-01 | Prince Douglas S | A-Award | 19,673.00 | $0.41 | $8,125 |